Myocet Design Features Sizelloading selected to maximize drug payload "Fluid"lipid matrix Targets encapsulated drug rapidly to MPS Avoids peak plasma levels and attenuates toxicities Creates"MPS Depot"from which drug re-enters blood stream Mimics slow infusion Maintains plasma and tissue AUC comparable to same dose of doxorubicin HCI OR MIOYMAISCA 8n02 inale' IAN 3200 IDVR13